Fulcrum Therapeutics vs Septerna
FULC and SEPN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How FULC and SEPN compare
Septerna is the larger company, worth 6.5 times as much as Fulcrum Therapeutics ($1.9B against $286M).
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | FULC | SEPN |
|---|---|---|
| Size and price | ||
| Market cap | $286M | $1.9B |
| Share price | $3.75 | $40.02 |
| Change, 1 year | −56.6% | 72.0% |
| Change, 5 years | −75.1% | – |
| Beta (5Y) | 1.36 | 0.70 |
| Employees | 55 | 130 |
| StockData Score | ||
| Total score | 8 | 8 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 19.4× |
| P/B | 0.9× (better) | 4.4× |
| FCF yield | −23.1% | −4.2% (better) |
| Fair value | – | $15.08 |
| Margin of safety | – | −165% |
| Growth | ||
| Revenue growth (TTM) | – | 337% |
| Profitability | ||
| Operating margin | – | −76.2% |
| Net margin | – | −61.3% |
| FCF margin | – | −80.6% |
| Return on equity | −32.4% | −14.4% (better) |
| Return on invested capital | −35.0% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 31.35 (better) | 4.84 |
| Altman Z-score | 10.37 (better) | 5.91 |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Buyback yield | −1.5% | – |
| Shareholder yield | −1.5% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 112% | 102% |
| Held by insiders | 34.7% | 27.9% |
| Insider net buying, 12 months | −$57.5M (better) | −$80.9M |
| Short interest, % of float | 12.9% | 10.0% |
Go deeper
- FULC stock overview
- FULC income statement
- FULC valuation and score
- SEPN stock overview
- SEPN income statement
- SEPN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.